Skip to content

Circulating Tumor DNA in Soft Tissue Sarcoma

Soft Tissue Sarcoma

This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma.
* Patients must have archival tissue from the diagnostic biopsy available.
* Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist.
* Age 18 years or older.
* Eastern Cooperative Group (ECOG) performance status ≤ 2
* Ability to understand and willing to sign a written informed consent document and comply with study requirements.

Exclusion Criteria:

* Patients with benign histology
* Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix.
* Patients with planned neo-adjuvant chemotherapy.
* Patients with regional nodal disease or unequivocal metastases
* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Study Location

Princess Margaret Cancer Centre
Princess Margaret Cancer Centre
Toronto, Ontario
Canada

Contact Study Team

Backup Contact

Limore Arones, R.N.

[email protected]
416-946-4501
Primary Contact

Albiruni Razak, M.D.

[email protected]
416-946-2000
Study Sponsored By
University Health Network, Toronto
Participants Required
More Information
Study ID: NCT03818412